MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 15, 2004; DOI: 10.1124/mol.104.003681


0026-895X/04/6606-1671-1678$20.00
Mol Pharmacol 66:1671-1678, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.003681v1
66/6/1671    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Triola, G.
Right arrow Articles by van Echten-Deckert, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Triola, G.
Right arrow Articles by van Echten-Deckert, G.

Specificity of the Dihydroceramide Desaturase Inhibitor N-[(1R,2S)-2-Hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in Primary Cultured Cerebellar Neurons

Gemma Triola, Gemma Fabrias, Mihaela Dragusin, Lars Niederhausen, Roland Broere, Amadeu Llebaria, and Gerhild van Echten-Deckert

Research Unit on Bioactive Molecules, Department of Biological Organic Chemistry, Institut d'Investigacions Químiques i Ambientals de Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona, Spain (G.T., G.F., A.L.); and Kekulé-Institut für Organische Chemie und Biochemie der Universität Bonn, Bonn, Germany (M.D., L.N., R.B., G.v.E.-D.)

Dihydroceramide desaturase catalyzes the conversion of the innocuous precursor dihydroceramide into a highly bioactive product ceramide. We studied the effect of N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11), the first inhibitor of this enzyme, in primary cultured cerebellar neurons. Although desaturase was efficiently inhibited (IC50 of 23 nM), the compound lost its specificity at higher concentrations. From 5 µM upward, GT11 also decreased de novo sphingolipid biosynthesis. Studies with two differentially labeled radioactive analogs of GT11 support that the inhibitor itself and not a downstream metabolic product, interferes with sphingolipid biosynthesis. It is interesting that serine palmitoyltransferase activity decreased in the presence of high concentrations of GT11 in intact cells, but not when added directly into cell homogenates. However, suppression of enzyme transcription could not be detected. But at high concentrations GT11 provoked an accumulation of sphingosine-1-phosphate and especially of dihydrosphingosine-1-phosphate, suggesting a decreased activity of sphingosine-1-phosphate lyase. Enzyme activity measurements indeed supported this assumption. Thus, at higher concentrations, GT11 interferes with lyase activity, inducing an accumulation of sphingoid base phosphates that, in turn, down-regulate serine palmitoyltransferase activity. At low concentrations, however, GT11 is the first specific inhibitor of dihydroceramide desaturase described so far. Considering the proapoptotic and proinflammatory effect of ceramide, GT11 could also turn out to be a novel cell-protective agent.


Received for publication June 10, 2004.

Accepted for publication September 14, 2004.

Address correspondence to: Dr. Gerhild van Echten-Deckert, Kekulé-Institut für Organische Chemie und Biochemie der Universität Bonn, Gerhard-Domagk-Strasse 1, 53121 Bonn, Germany. E-mail: g.echten.deckert{at}unibonn.de




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
H. Wang, B. J. Maurer, Y.-Y. Liu, E. Wang, J. C. Allegood, S. Kelly, H. Symolon, Y. Liu, A. H. Merrill, Jr., V. Gouaze-Andersson, et al.
N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing
Mol. Cancer Ther., September 1, 2008; 7(9): 2967 - 2976.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. Bandhuvula, H. Fyrst, and J. D. Saba
A rapid fluorescence assay for sphingosine-1-phosphate lyase enzyme activity
J. Lipid Res., December 1, 2007; 48(12): 2769 - 2778.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Kraveka, L. Li, Z. M. Szulc, J. Bielawski, B. Ogretmen, Y. A. Hannun, L. M. Obeid, and A. Bielawska
Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells
J. Biol. Chem., June 8, 2007; 282(23): 16718 - 16728.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics